Gregory M. Glenn, President, R&D at NOVAVAX INC (NVAX), sold 17,766 shares at $166.89 ($3.0M) on 2021-11-16, disclosed to the SEC on 2021-11-17.
Open-market sale of $3.0M NVAX by President, R&D. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $172.02 | 1,183 | $203K | 6.7% |
| 2 | $172.02 | 1,183 | $204K | 6.7% |
| 3 | $166.89 | 500 | $83K | 2.8% |
| 4 | $167.95 | 1,472 | $247K | 8.2% |
| 5 | $167.95 | 1,472 | $247K | 8.2% |
| 6 | $168.91 | 1,326 |
| $224K |
| 7.4% |
| 7 | $168.91 | 1,326 | $224K | 7.4% |
| 8 | $170.26 | 4,352 | $741K | 24.6% |
| 9 | $170.26 | 4,352 | $741K | 24.6% |
| 10 | $170.94 | 600 | $103K | 3.4% |
| Total | $169.84 avg | 17,766 | $3.0M | 100% |
| Filing → |
| NVAX | SELL | 2021-12-09 | $1.6M | — | Filing → |
| NVAX | SELL | 2021-12-02 | $3.2M | — | Filing → |
| NVAX | SELL | 2021-11-30 | $719K | — | Filing → |